119 related articles for article (PubMed ID: 16426744)
1. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature.
Segers J; Di Fazio V; Ansiaux R; Martinive P; Feron O; Wallemacq P; Gallez B
Cancer Lett; 2006 Nov; 244(1):129-35. PubMed ID: 16426744
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):186-92. PubMed ID: 12203100
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.
Kaicker S; McCrudden KW; Beck L; New T; Huang J; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ
Int J Oncol; 2003 Dec; 23(6):1651-5. PubMed ID: 14612937
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.
Ansiaux R; Baudelet C; Jordan BF; Beghein N; Sonveaux P; De Wever J; Martinive P; Grégoire V; Feron O; Gallez B
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):743-50. PubMed ID: 15701864
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies.
Kohandel M; Kardar M; Milosevic M; Sivaloganathan S
Phys Med Biol; 2007 Jul; 52(13):3665-77. PubMed ID: 17664569
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Heere-Ress E; Boehm J; Thallinger C; Hoeller C; Wacheck V; Birner P; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2005 Aug; 125(2):201-6. PubMed ID: 16098027
[TBL] [Abstract][Full Text] [Related]
8. Effect of acetyl 11-keto beta-boswellic acid on metastatic growth factor responsible for angiogenesis.
Singh SK; Bhusari S; Singh R; Saxena A; Mondhe D; Qazi GN
Vascul Pharmacol; 2007 May; 46(5):333-7. PubMed ID: 17257903
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM
Clin Cancer Res; 2004 Sep; 10(17):5949-56. PubMed ID: 15355928
[TBL] [Abstract][Full Text] [Related]
13. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
[TBL] [Abstract][Full Text] [Related]
14. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
Albertsson P; Lennernäs B; Norrby K
Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
[TBL] [Abstract][Full Text] [Related]
16. The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
Liu Y; Li H; Matsui O
J Gastroenterol Hepatol; 2009 Jun; 24(6):1077-81. PubMed ID: 19220680
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
19. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
20. [Using thalidomide against pathological neovascularization].
Eisenkraft A; Luria S; Robenshtok E; Hourvitz A
Harefuah; 2003 Mar; 142(3):212-6, 237. PubMed ID: 12696477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
